PDE4 inhibitors can exert a range of anti-inflammatory effects relevant to the neutrophilic inflammatory milieu in COPD, including inhibition of TNF production by alveolar macrophages and monocytes and inhibition of ROS production by neutrophils [104]. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.